Markets Turn More Bullish Ahead Of Earnings

The CNN Money Fear and Greed index showed further improvement in the overall sentiment among US investors. The Dow Jones index snapped the four-session winning streak as investors weighed the recent earnings results.

The CNN Money Fear and Greed index showed further improvement in the overall sentiment among US investors.

The Dow Jones index snapped the four-session winning streak as investors weighed the recent earnings results.

The Goldman Sachs Group, Inc. (NYSE:GS) shares dropped 6.4% on Tuesday after the bank reported downbeat earnings for the fourth quarter.

The Dow closed lower by around 392 points to 33,910.85 on Tuesday. The S&P 500 fell 0.20% to 3,990.97, while the Nasdaq Composite rose 0.14% to settle at 11,095.11 in the session.

Investors are awaiting earnings results from The Charles Schwab Corporation (NYSE:SCHW), The PNC Financial Services Group, Inc. (NYSE:PNC), and Alcoa Corporation (NYSE:AA) today.

At a current reading of 65.0, the index remained in the “Greed” zone, compared to a previous reading of 63.0.

What is CNN Business Fear & Greed Index?

The Fear & Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.

Read Next: Over $10 Million Bet On DiamondHead Holdings? Check Out These 4 Stocks Insiders Are Buying

Total
0
Shares
Related Posts
Read More

Alexandria Real Estate Equities, Inc. Announces Accelerated Delivery Of Moderna’s New 462,100 RSF HQ And R&D Center, Designed To Be The Most Sustainable Laboratory Building In Cambridge, At 325 Binney Street On The One Kendall Square Mega Campus

Alexandria earned the 2023 Visionary Award from the Cambridge Chamber of Commerce for developing325 Binney Street, which will support Moderna as it advances a pipeline of mRNA medicines thatleverage its paradigm-shifting

ARE